Collaboration

Scientists in laboratory
#Antibiotics #Antimicrobial resistance (AMR) #Antimicrobials #Collaboration #Cresset Discovery #Partnership #Screening

Virtual screening partners to find new antimicrobial drugs

Cresset Discovery and the University of Exeter have entered a collaboration to discovery novel antimicrobial drugs.  Cresset Discovery will use virtual screening to identify promising new candidates, building on research led by Dr Stefano Pagliara.  Virtual screening enables chemists to explore new chemical space, discover… Read More

#News

Organ-on-a-chip
#Bioavailability #CN Bio #Collaboration #FDA #In vitro #Organ-on-a-chip

FDA expands organ-on-a-chip research collaboration

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System.   The system will initially be investigated for improving the preclinical estimation of human drug… Read More

#News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

Catch up with the latest DDW Highlights episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Once again, research partnerships and licence agreements have dominated the news… Read More

#News

Virus-like particles
#Biopharmaceuticals #Cell and gene therapy #Collaboration #Gene delivery #Gene therapy #Partnership #Vector BioPharma

Vector and iBET collaborate to accelerate gene delivery platform

Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform.  Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins.  Lorenz Mayr, CEO at Vector BioPharma, said: “Collaboration with industry-leading… Read More

#Business & Investment #News

#Collaboration #Drug development #Drug discovery #Mergers and acquisitions #Partnership

This week in drug discovery (9-13 January)

News round-up for 9-13 January by DDW Digital Content Editor Diana Spencer. Once again, research partnerships and licence agreements have dominated the news this week, as drug discovery companies seek new ways to combine their expertise to address unmet medical needs.  The top stories: … Read More

#News

Neurons in Parkinson's disease
#Biologics / Biotechnology #Collaboration #Drug discovery #Library screening #Neurodegenerative disorders #Partnership #Sironax #X-Chem

Research partners will target neurodegenerative disease

X-Chem and Sironax have agreed a research partnership, in which X-Chem will use its DEL platform to support Sironax’s drug discovery pipeline.   Through the collaboration, X-Chem will screen its DNA-encoded libraries (DEL) against difficult-to-drug targets implicated in neurodegenerative disease to discover hits. In turn, Sironax will prosecute these hits into… Read More

#Business & Investment #News

Research scientists in laboratory
#Abbie #Antibodies #Antibody-based therapeutics #Cancer research #Collaboration #Immunome #Oncology #Partnership

Collaboration to identify up to 10 novel target-antibody pairs

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine.  Steve Davidsen, Vice President, Oncology Discovery Research, AbbVie. “Immunome’s approach has the potential to unlock novel cancer biology and yield multiple… Read More

#Business & Investment #Cancer Research #News

Research lab
#Cancer research #circular RNAs #Collaboration #Esperovax #Ginkgo Bioworks #High throughput screening #Oncology #Partnership #RNA

Alliance to develop circular RNA-based therapeutics

Esperovax and Ginkgo Bioworks have agreed a partnership to develop circular RNAs (circRNAs) for a variety of therapeutic applications.   Initially, the companies will work to develop circRNAs harbouring payloads to specifically target colorectal cancer by inducing cell death only in cancerous cells.  CircRNAs represent an… Read More

#Cancer Research #News

RNA
#Collaboration #Orbit Discovery #Partnership #Peptides #RNA #SanegeneBio #Screening

New partners hope to identify targeting peptides for RNAi drugs

Orbit Discovery and start-up SanegeneBio have entered into a Master Service Agreement to identify tissue-specific delivery of a wide range of RNA therapeutics.  The agreement covers activities ranging from hit ID to cell-based internalisation studies, with an option for Sanegene to further develop the hits resulting from the screening activities. … Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Cancer drug targets #Cancer research #Collaboration #Oncology #Partnership

AI-powered cancer simulations enable drug targeting

Cancer Research Horizons and biotech company Turbine have announced a partnership to solve complex diseases.   The partnership will utilise Turbine’s Simulated Cells platform to identify target patient populations who could benefit from CDC7 inhibitor therapy with Cancer Research Horizons’ lead compound CRT’2199.   CRT’2199 originates from Cancer Research Horizons’ Therapeutic Innovation. Read More

#Business & Investment #Cancer Research #News

Antibody drug conjugate
#Antibodies #Antibody drug conjugate (ADC) #Collaboration #License agreement #Partnership #Precision medicine

Collaboration will combine ADC technology and precision therapeutics

Synaffix and Hummingbird Bioscience have entered into a licensing agreement that it is hoped will enable Hummingbird Bio to develop an antibody drug conjugate (ADC) programme using Synaffix technology.   Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,… Read More

#Business & Investment #News

Detecting antibodies in a lab
#Antibodies #Antibody #Antibody drug conjugate (ADC) #Antibody-based therapeutics #Collaboration #Drug discovery #Market reporting #Partnership

Partnerships and collaborations fuel antibodies market growth

Increasing collaborations and partnerships between market players are expected to contribute to significant growth in the antibodies market between 2022 and 2030, ResearchAndMarkets.com predicts.   In one example from March 2022, Sanofi and Seagen announced an exclusive collaboration agreement to design, develop, and market antibody-drug conjugates (ADCs) for up to three… Read More

#Business & Investment #Market Reports #News

Two scientists working in a research laboratory
#Antibody #Antibody drug conjugate (ADC) #Cancer research #Collaboration #Merck #Mersana Therapeutics #Partnership #Tumours

Research partners hope to develop novel antibody-drug conjugates

Mersana Therapeutics and a subsidiary of Merck have entered a research collaboration to discover novel Immunosynthen antibody-drug conjugates (ADCs) directed against up to two targets.  Under the terms of the agreement, Mersana will develop novel ADC product candidates against up to two targets utilising its Immunosynthen platform to conjugate proprietary… Read More

#Business & Investment #News

Drug screening in laboratory
#AI / data analytics / healthtech / informatics #Artificial intelligence (AI) #Collaboration #Drug targets #High throughput screening #Partnership #Phenotyping #PhoreMost #ThinkCyte

New research collaboration to advance AI based drug discovery

PhoreMost and ThinkCyte have entered a strategic research partnership aimed at advancing modern phenotypic drug screening using artificial intelligence (AI).  The partnership leverages both companies’ technologies in high-throughput drug discovery, PhoreMost’s phenotypic screening platform, SITESEEKER, and ThinkCyte’s AI-driven cell characterisation and sorting platform, Ghost Cytometry. … Read More

#News

Multiple myeloma
#Arcellx #Cancer research #Cell therapy #Collaboration #Kite #Myeloma #Partnership #T cell activation

Partnership will co-develop cell therapy for multiple myeloma

Kite and Arcellx have entered a global strategic collaboration to co-develop and co-commercialise CART-ddBCMA for the treatment of patients with relapsed or refractory multiple myeloma.  Currently in Phase II clinical development, CART-ddBCMA is an investigational cell therapy product comprising autologous T cells that have been genetically modified… Read More

#Cancer Research #News

Central nervous system
#CNS #Collaboration #Genetics / genomics #Partnership #Pharmaceuticals #Research & development #Target identification

Collaboration will focus on therapy targets for CNS disorders

PrecisionLife and Ono Pharmaceutical have agreed a multi-target discovery and validation partnership.   The R&D collaboration will leverage PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets and patient stratification biomarkers in central nervous system (CNS) disorders for development by Ono.  PrecisionLife analyses multi-modal datasets including genomic, clinical, and epidemiological data… Read More

#Business & Investment #News